Ratings Supriya Lifescience Limited

Equities

SUPRIYA

INE07RO01027

End-of-day quote NSE India S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
377.6 ^INR	-0.32%		-1.73%	+19.98%

02-07	Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
02-07	Supriya Lifescience Limited Announces Approval of Capital Expenditure at Ambernath Site for CDMO Facility	CI

Summary

The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses

The firm trades with high earnings multiples: 26.41 times its 2024 earnings per share.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SUPRIYA LIFESCIENCE LIMITED	+19.98%	365M	D+
ELI LILLY AND COMPANY	+32.36%	709B	C+
NOVO NORDISK A/S	+30.77%	595B	B
JOHNSON & JOHNSON	-1.60%	367B	C+
MERCK & CO., INC.	+20.07%	334B	B-
ABBVIE INC.	+6.04%	289B	C+
ASTRAZENECA PLC	+14.77%	239B	B+
NOVARTIS AG	+9.13%	211B	B-
ROCHE HOLDING AG	-3.97%	203B	A+
AMGEN INC.	+9.27%	171B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes